Latest From Geron Corp.
The company outlined pharma growth drivers, including 14 currently marketed medicines that will achieve $1bn or more in sales by 2020 and 10 new filings through 2023.
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.
Janssen is dropping the telomerase inhibitor as imetelstat nears the conclusion of Phase II in myelodysplastic syndrome and myelofibrosis, but Geron has $183m in cash on hand that it will use to take the drug forward on its own in one or both indications.
- Antisense, Oligonucleotides
- Large Molecule
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Geron Corp.
- Senior Management
John A Scarlett, MD, Pres. & CEO
Olivia K Bloom, EVP, Fin. & CFO
Melissa A Behrs, EVP, Bus. Dev.
Andrew J Grethlein, PhD, EVP, Dev. & Technical Operations
Aleksandra Rizo, CMO
- Contact Info
Phone: (650) 473-7700
149 Commonwealth Dr.
Menlo Park, CA 94025
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.